Key Points
- Ivan Hyep, CFO has been selling shares recently — notably 605 shares on Nov 21 at $18.15 (~$10,981) and 17,795 shares on Nov 24 at $18.55 (~$330,097) — and now holds 145,355 shares valued at about $2.64M.
- Bicara's fundamentals and sentiment are mixed: the company has a $1.01B market cap, reported a quarterly EPS miss (‑$0.67 vs. ‑$0.55 expected), and carries a consensus "Moderate Buy" analyst target of $29.67.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 605 shares of the company's stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $18.15, for a total value of $10,980.75. Following the completion of the sale, the chief financial officer owned 145,355 shares in the company, valued at $2,638,193.25. The trade was a 0.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Ivan Hyep also recently made the following trade(s):
- On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.55, for a total value of $330,097.25.
- On Thursday, October 9th, Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.23, for a total value of $116,945.45.
- On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total transaction of $332,405.68.
- On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.21, for a total transaction of $102,467.67.
- On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.17, for a total transaction of $118,359.38.
Bicara Therapeutics Stock Performance
Shares of NASDAQ BCAX opened at $18.46 on Wednesday. The company has a market capitalization of $1.01 billion, a PE ratio of -8.24 and a beta of -0.76. The company's fifty day moving average price is $15.59 and its 200 day moving average price is $12.69. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $22.67.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.12). On average, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Institutional Investors Weigh In On Bicara Therapeutics
Several large investors have recently bought and sold shares of BCAX. CWM LLC purchased a new position in shares of Bicara Therapeutics in the first quarter valued at approximately $29,000. Legal & General Group Plc increased its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after purchasing an additional 1,474 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock valued at $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in Bicara Therapeutics during the 1st quarter worth $52,000.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on BCAX shares. Wells Fargo & Company upped their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 11th. Piper Sandler began coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective on the stock. HC Wainwright reduced their target price on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Wedbush reiterated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Monday, November 10th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bicara Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $29.67.
View Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
